You are here
TOMEGAVAX, INC.
UEI: NUE6Q16X2GL1
# of Employees: 11
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
A Cytomegalovirus-based therapeutic vaccine for chronic hepatitis B
Amount: $1,685,089.00Abstract Although an efficient prophylactic vaccine is available for hepatitis B virusHBVchronic hepatitis BCHBaffects up tomillion people worldwideand despite advances remains mostly incurableIn adul ...
SBIRPhase II2018Department of Health and Human Services National Institutes of Health -
A Cytomegalovirus based therapeutic vaccine for chronic hepatitis B
Amount: $297,434.00Abstract Although an efficient prophylactic vaccine is available for hepatitis B virus HBV chronic hepatitis B CHB affects up to million people worldwide and despite advances remains mostly ...
SBIRPhase I2017Department of Health and Human Services National Institutes of Health -
A Cytomegalovirus Vectored Chagas Disease Therapeutic Vaccine
Amount: $224,959.00Abstract The goal of this project is to utilize cytomegalovirus CMV vectors to develop a therapeutic vaccine against Trypanosoma cruzi the causative agent of Chagas disease Although the most commo ...
SBIRPhase I2016Department of Health and Human Services National Institutes of Health -
A Cytomegalovirus based therapeutic vaccine against oncogenic human papillomaviruses
Amount: $1,876,513.00Abstract High risk human papillomaviruses HPV cause cervical cancer the second most common neoplasm among women globally and a large proportion of oropharyngeal cancers Although prophylactic vacc ...
SBIRPhase II2016Department of Health and Human Services National Institutes of Health -
An effector memory T cell-based therapeutic cervical cancer vaccine
Amount: $224,671.00DESCRIPTION (provided by applicant): The longterm goal of this project is to utilize cytomegalovirus (CMV) vectors carrying oncogenes of high risk human papillomaviruses (HPV) as novel therapeutic va ...
SBIRPhase I2014Department of Health and Human Services National Institutes of Health -
CMV Vectored Herpes Simplex Vaccine
Amount: $299,863.00DESCRIPTION (provided by applicant): The longterm goal of this project is to utilize cytomegalovirus (CMV) vectors in the development of a therapeutic vaccine against herpes simplex virus 2 (HSV-2), t ...
STTRPhase I2014Department of Health and Human Services National Institutes of Health -
A human cytomegalovirus-based immunotherapy for HIV-1
Amount: $2,965,403.00DESCRIPTION The ultimate goal of this project is to develop an immunotherapy for human immunodeficiency virus HIV based on a spread deficient cytomegalovirus CMV derived vaccine expressing andq ...
SBIRPhase II2014Department of Health and Human Services National Institutes of Health -
A Synthetic Human Cytomegalovirus Vaccine Platform
Amount: $573,060.00DESCRIPTION (provided by applicant): The goal of this project is to synthesize, based on genomic sequence information, a human cytomegalovirus (HCMV) strain with demonstrated ability to establish per ...
STTRPhase I2013Department of Health and Human Services National Institutes of Health -
Spread-deficient HCMV-vectored vaccines
Amount: $299,835.00DESCRIPTION (provided by applicant): The goal of this project is to establish human cytomegalovirus (HCMV) as a new human vaccine vector platform. In non-human primate models, CMV-vectored vaccines ha ...
SBIRPhase I2012Department of Health and Human Services National Institutes of Health
